Haberler | Bel soğukluğu enjeksiyonsuz tedavi edilebilir mi? Yeni antibiyotik eşdeğer etkinlik gösterdi
İlaçlara dirençli bel soğukluğu dünya genelinde artarken, a new single-dose oral antibiotic offers a rare positive development. A large international phase 3 trial published January 3 in The Lancet found that zoliflodacin was noninferior to standard treatment for uncomplicated urogenital gonorrhea, without injections or a complex regimen.
Gonorrhea is one of the most common sexually transmitted infections, causing over 82 million new cases annually. Neisseria gonorrhoeae mainly infects the reproductive tract but can also affect the throat and rectum. Untreated infection can cause pelvic inflammatory disease and infertility. Resistance to multiple antibiotics has narrowed treatment options and become a major public health concern.
Standard international treatment generally combines two antibiotics: an injection of ceftriaxone followed by oral azithromycin. Although effective, it requires injection facilities and careful medical management, limiting use in low-resource settings.
The open-label, randomized, controlled, noninferiority phase 3 trial included more than 900 participants in the United States, South Africa, Thailand, Belgium, and the Netherlands. They received either single-dose oral zoliflodacin or standard ceftriaxone plus azithromycin.
Zoliflodacin cured over 90% of urogenital infections, comparable to standard therapy. It was generally well tolerated, with adverse events similar to existing treatments and no new serious safety concerns.
The authors noted that phase 3 trials are a key step before approval, confirming efficacy and assessing safety in larger populations. The findings suggest potential for real-world use.
The FDA is reviewing the drug. If approved, zoliflodacin could become the first single-dose oral antibiotic with a new mechanism for gonorrhea. It could simplify care, reduce reliance on injections, and support community treatment and prevention programs worldwide.
Researchers stressed that a new antibiotic class is vital to reproductive health as resistance spreads and options narrow. Approval could reshape both clinical care and public health strategies.
Haberler | Bel soğukluğu enjeksiyonsuz tedavi edilebilir mi? Yeni antibiyotik eşdeğer etkinlik gösterdi
Haberler | Bel soğukluğu enjeksiyonsuz tedavi edilebilir mi? Yeni antibiyotik eşdeğer etkinlik gösterdi
İlaçlara dirençli bel soğukluğu dünya genelinde artarken, a new single-dose oral antibiotic offers a rare positive development. A large international phase 3 trial published January 3 in The Lancet found that zoliflodacin was noninferior to standard treatment for uncomplicated urogenital gonorrhea, without injections or a complex regimen.
Gonorrhea is one of the most common sexually transmitted infections, causing over 82 million new cases annually. Neisseria gonorrhoeae mainly infects the reproductive tract but can also affect the throat and rectum. Untreated infection can cause pelvic inflammatory disease and infertility. Resistance to multiple antibiotics has narrowed treatment options and become a major public health concern.
Standard international treatment generally combines two antibiotics: an injection of ceftriaxone followed by oral azithromycin. Although effective, it requires injection facilities and careful medical management, limiting use in low-resource settings.
The open-label, randomized, controlled, noninferiority phase 3 trial included more than 900 participants in the United States, South Africa, Thailand, Belgium, and the Netherlands. They received either single-dose oral zoliflodacin or standard ceftriaxone plus azithromycin.
Zoliflodacin cured over 90% of urogenital infections, comparable to standard therapy. It was generally well tolerated, with adverse events similar to existing treatments and no new serious safety concerns.
The authors noted that phase 3 trials are a key step before approval, confirming efficacy and assessing safety in larger populations. The findings suggest potential for real-world use.
The FDA is reviewing the drug. If approved, zoliflodacin could become the first single-dose oral antibiotic with a new mechanism for gonorrhea. It could simplify care, reduce reliance on injections, and support community treatment and prevention programs worldwide.
Researchers stressed that a new antibiotic class is vital to reproductive health as resistance spreads and options narrow. Approval could reshape both clinical care and public health strategies.
Haber kaynağı:
İnternetten derlenmiştir